Astellas and Teijin Pharma Extend Febuxostat Partnership To China
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Astellas will work with Teijin Pharma to market the latter's febuxostat in China and Hong Kong, expanding their partnership on the first new gout drug in 40 years